Deals channel feed – Endpoints News

Deals channel feed

Merck drops out of a $125M KRAS alliance with Moderna, taking a step away from the Covid-19 star

4 years ago

Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets

4 years ago

Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0

4 years ago

BioNTech signs immunotherapy deal with Medigene as post-Covid strategy takes shape

4 years ago

Roche signs neurodegeneration pact with stealthy biotech, primarily focusing on ALS

4 years ago

J&J jumps on the RNA bandwagon, inking discovery deal with Remix for a potentially new class of drugs

4 years ago

Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer

4 years ago

Hunting deals on all fronts, Merck enlists drug discovery biotech on search for protein modulators

4 years ago

Gilead rejigs HIV immunotherapy pact, grabs a stake in biotech partner

4 years ago

Revealing heavy losses in new SEC filing, video game therapeutic maker Akili details an uncertain financial future

4 years ago

Small pain drug player gets snapped up in $604M buyout — and the axe will soon fall

4 years ago

The 2022 top 100 biopharma investors: A look back on boom times

4 years ago

Merck KGaA enlists little AI player on protein degrader discovery

4 years ago

Albert Bourla has some plans for Pfizer's huge Covid cash haul. Hint: 'Acquisitions are very much in the cards'

4 years ago

Bayer bails on chronic cough drug from Evotec, putting the kibosh on lead med in multi-target collaboration

4 years ago

AstraZeneca dumps off a mid-stage PAD hopeful, sounding retreat from a packed market

4 years ago

Amgen, looking for a path into red-hot 'molecular glues,' inks a deal with Plexium for 2 programs, potentially more

4 years ago

J&J bets $40M cash on biotech's ADC tech and its battle-tested CEO — with biobucks adding to $1B

4 years ago

With new buyout, J&J jumps back in on a storied but troubled Holy Grail target

4 years ago

Cash-strapped antibiotics player Entasis could go private with a small-dollar buyout offer on the table

4 years ago

How UCB beat 2 other bidders to land $1.9B buyout of Zogenix and its epilepsy drug

4 years ago

Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact

4 years ago

Oxford Biomedica enters the AAV manufacturing world, buying Homology's in-house business

4 years ago

Under the gun with Aduhelm floundering, Biogen sells its stake in biosimilars business for $2.3B

4 years ago

First page Previous page 62 63 646566 67 68 Next page Last page